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The role of dipeptidyl peptidase – 4
inhibitors in diabetic kidney disease
Usha Panchapakesan* and Carol Pollock
Renal Research Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW,
Australia
Despite major advances in the understanding of the molecular mechanisms that underpin
the development of diabetic kidney disease, current best practice still leaves a significant
proportion of patients with end-stage kidney disease requiring renal replacement therapy.
This is on a background of an increasing diabetes epidemic worldwide. Although kidney
failure is a major cause of morbidity the main cause of death remains cardiovascular
in nature. Hence, diabetic therapies which are both “cardio-renal” protective seem
the logical way forward. In this review, we discuss the dipeptidyl peptidase 4 (DPP4)
inhibitors (DPP4inh), which are glucose-lowering agents used clinically and their role in
diabetic kidney disease with specific focus on renoprotection and surrogate markers of
cardiovascular disease. We highlight the novel pleiotropic effects of DPP4 that make it an
attractive additional target to combat the fibrotic and inflammatory pathways in diabetic
kidney disease and also discuss the current literature on the cardiovascular safety profile
of DPP4inh. Clearly, these observed renoprotective effects will need to be confirmed by
clinical trials to determine whether they translate into beneficial effects to patients with
diabetes.
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The Incretin System
Under physiological conditions, blood glucose is tightly regulated by a number of mechanisms
including the incretin systemof hormones that are secreted in response to ameal. Glucagon like pep-
tide 1 (GLP-1) and gastrointestinal peptide (GIP) are released from the gut and regulate postprandial
glucose excursions. Proglucagon is secreted by the intestinal mucosa and is subsequently cleaved
to GLP-1, which acts on the GLP-1 receptor in the pancreas in a glucose-dependent manner and
functions to stimulate pancreatic insulin release and suppress glucagon secretion with the net effect
of regulating postprandial glucose (1). The half-life of GLP-1 is very short (minutes) as it is rapidly
degraded by dipeptidyl-peptidase 4 (DPP4). DPP4 cleaves two amino acids at the amino terminal
end of peptides that have a proline (or less commonly an alanine) at the penultimate position (2).
Hence GLP-1 (7–36) amide is cleaved to GLP-1 (9–36) amide, which is the major circulating form.
GLP-1 (9–36) does not have insulinotropic effects.
Dipeptidyl peptidase 4 inhibitors (DPP4inh) are novel oral diabetic agents used to lower blood
glucose in patients with type 2 diabetesmellitus. They inhibit DPP4, which degrades GLP-1 resulting
in raised endogenous GLP-1. They promote insulin release and inhibit glucagon secretion, causing
lower blood glucose. Favorable aspects of DPP4inh in comparison to other diabetic agents include
its oral formulation, reduced risk of hypoglycemia and lack of weight gain. In addition, DPP4inh
have benefits beyond glucose lowering as DPP4 cleaves a host of peptides/substrates in addition to
GLP-1, resulting in a broad range of altered biological functions.
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In this review, we focus on the pleiotropic properties of DPP4
beyond glucose lowering with specific reference to renoprotection
and cardiovascular aspects. This is summarized in Figure 1. The
clinical relevance of this is the fact that up to a third of patientswith
diabetes suffers renal complications with the main cause of mor-
tality being cardiovascular in origin. Hence, continued inquiry
into mechanisms of renal failure in patients with diabetes that will
lead to examination of novel strategies to limit cardiovascular and
renal disease is the logical step forward.
DPP4 – A Multifunctional Protein
DPP4 is a 110-kDa type 11 integral membrane glycoprotein and
is expressed ubiquitously in most organs and cell types. DPP4
exists in both a soluble and membrane bound form, both of
which are capable of proteolytic activity. The soluble form in the
circulation is thought to arise from shedding of the membrane
boundDPP4 and is the target forDPP4inh as hypoglycemic agents
in clinical use (1). Identified substrates include GLP-1, regulated
on activation, normal T cell expressed and secreted (RANTES),
which is relevant in renal disease (3, 4), brain natriuretic peptide
1–32 (5, 6), neuropeptide Y (7), high mobility group protein 1
(HMGB1) (8), and Substance P (9). More recently, aggregates
of amyloid beta peptides (pathological hallmarks of Alzheimers
disease) have also been identified as substrates of DPP4 (10).
Many substrates have been identified as being pharmacological
substrates (cleaved in vitro) but are not cleaved in vivo. Hence,
this proteolytic effect can either lead to a gain in function, a
loss of function or have no functional significance. An example
of the physiological relevance of these non-GLP-1 substrates is
highlighted by DPP4 truncation of certain chemokines, colony-
stimulating factors, and interleukins, which have recently been
linked to regulation of hematopoietic stem/progenitor cells where
DPP4inh has been shown to enhance engraftment of cord blood
in patients with hematological malignancies (11, 12).
The membrane bound form of DPP4, expressed on the sur-
face of many cell types including kidney tubular cells, endothe-
lial cells and T cells, is of major interest with respect to the
pleiotropic actions of DPP4. Membrane-bound DPP4 also exerts
non-enzymatic actions by virtue of co-localizing with other
membrane proteins and modulating their intrinsic actions (2,
13). DPP4 is known to interact with adenosine deaminase (14),
caveolin 1 (15, 16), cation independent mannose 6 phosphate
DPP4inh
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FIGURE 1 | This is a schematic diagram summarizing the glucose
lowering and pleiotropic effects of DPP4 inhibition, which may be
relevant in cardiorenal protection.
receptor (CIM6PR) (also known as insulin growth factor recep-
tor 2) (17, 18), and glypican 3 (19). Interestingly, it has been rec-
ognized that DPP4 interacts with human coronavirus-EMC spike
protein and acts as a receptor for this virus, which provides new
knowledge to facilitate the direction of interventional strategies in
related respiratory illness (20).
DPP4 and the Kidney
The proteolytic functions of DPP4 in the kidney have been
described using liquid chromatography mass spectrometry-based
peptidomics, where kidney tissue from DPP4+/+ and DPP4 / 
mice were compared. This revealed 10 peptides regulated by
DPP4 in vivo (21, 22). Further studies with brush border mem-
branes showed that aminopeptidase activity is required to gen-
erate DPP4 substrates. This suggests that DPP4 is involved in
the extracellular catabolism of proteins in the kidney, specifically
the degradation/catabolism of proline-containing peptides (23).
As DPP4 is present on the brush border (apical side) of kidney
proximal tubular cells, DPP4 inhibition is likely to alter the degra-
dation/regulation of peptides in the lumen and thus influence the
tubular cell structure or function in diabetes. Identifying the func-
tionally relevant renal substrates of DPP4 will help us understand
and anticipate long-term effects of DPP4 inhibition on the kidney
in patients with diabetes. The tools required to validate identified
substrates are limited given that specific antibodies must be able
to distinguish between cleaved and non-cleaved peptides, which
differ by only two amino acids at the N-terminal end.
Transforming growth factor beta 1 (TGFβ1) is a major driver
of fibrosis in diabetic kidney disease. We have reported that
linagliptin, a DPP4inh, reduces high glucose-induced active
TGFβ1 in human kidney proximal tubular cells (24) with a down-
stream reduction in phosphorylated smad2 and fibronectin tran-
scription and expression. As high-glucose-induced total secreted
TGFβ1 was unchanged by linagliptin, we postulated that the
mechanism was related to interference with the conversion from
latent to active TGFβ1. TGFβ1 is secreted in a latent form and
requires a complex interplay of soluble signaling molecules in the
activation process, which releases it from the latency associated
peptide (LAP) (25). Once released from the LAP, the unbound
TGFβ1 can then bind to its receptor to initiate cell signaling via
the Smad pathway. In pursuing this further, we showed that that
the interaction between CIM6PR and DPP4 is “switched on” by
high glucose, and hence is maximally modulated by linagliptin
in this environment. In the presence of excess M6P, the CIM6PR
binding sites become saturated, resulting in the reduction in
CIM6PR/DPP4 interaction, which would imply that the interac-
tion is occurring through a M6P residue on the DPP4 molecule.
The fact that linagliptin also reduced this interaction, suggests a
M6P-mediatedmechanism, which is independent of GLP-1 as our
in vitro system is lacking in GLP-1 (unpublished data). This novel
finding adds to the body of knowledge that DPP4 inhibition can
exert antifibrotic effects through its non-proteolytic properties.
This is discussed further below with respect to endothelial cell
dysfunction.
In interpreting preclinical studies, it is important to appre-
ciate the confounding aspects of concomitant glucose lowering
by DPP4inh. There are two studies, which have looked at the
Frontiers in Immunology | www.frontiersin.org August 2015 | Volume 6 | Article 4432
Panchapakesan and Pollock DPP4 in diabetic kidney disease
effect of DPP4inh (using vildagliptin and sitagliptin) on the dia-
betic animal kidney and both show renoprotection. However,
the HbA1c (hemoglobin A1C) in the DPP4inh-treated diabetic
animals was lower than in the diabetic-control animals (26, 27).
So in both these in vivo studies, it is difficult to conclude that the
renal effects of DPP4inh lie above and beyond glucose lowering.
Kanasaki and colleagues investigate the antifibrotic properties
of linagliptin in a Type 1 model of diabetic nephropathy and
showed that after 4 weeks, linagliptin ameliorated diabetic kid-
ney fibrosis, an observation that occurred in association with
the inhibition of endothelial-mesenchymal transition (EndMT)
and the restoration of microRNA29s (28). An insulin-deficient
model of diabetes enables evaluation of the effects of the DPP4inh
independent of glycemic control as DPP4inh will not have a sig-
nificant hypoglycemic effect due to the lack of a significant insulin
responsemediated byGLP-1. As a result, the new findings provide
information regarding renal benefit of linagliptin independent of
glycemic control.
The antifibrotic properties of DPP4inh have also been shown
in other models of kidney fibrosis such as the unilateral ureteral
obstruction (UUO) model (29). In this TGFβ-driven model,
LC15-0444 (aDPP4inh) reduced inflammatory and fibroticmark-
ers such as levels of phosphorylated Smad2/3, TGFβ1, toll-like
receptor 4, HMGB1, NADPH oxidase 4, and nuclear factor kappa
B. However, this study lacked specific mechanistic data to explain
the findings.
There is also experimental evidence to suggest that DPP4 is
involved in the advanced glycation end product – receptor axis,
which is highly relevant in diabetic kidney disease. Both DPP4
deficiency and linagliptin reduced renal damage in animal models
of Type 1 diabetic nephropathy (30, 31). Themechanismproposed
was related to reducing endothelial cell oxidative stress.
Likewise, DPP4inh has been explored in animal models of obe-
sity, insulin resistance, and renal disease. The DPP4inh MK0626
was shown to reduce obesity-induced renal injury (MK0626) and
attenuated filtration barrier injury and oxidant stress in the zucker
obese rat (linagliptin) (32, 33).
Endothelial dysfunction is an inherent aspect of diabetic kidney
disease. Shi et al. demonstrated that in endothelial cells, DPP4 and
integrin β1 physically interacted. DPP4-associated endothelial to
mesenchymal transition was inhibited by integrin β1 deletion. In
addition, DPP4 or integrin β1 deficiency resulted in the inhibition
of TGFβ2-stimulated heterodimer formation of TGFβ receptors.
Along with this, the interaction between DPP4 and integrin β1
induced vascular endothelial growth factor receptor (VEGF-R) 1
expression with the concomitant suppression of VEGF-R2 levels
(34). Importantly, linagliptin was able to reduce the TGFβ2 physi-
cal interaction between integrin and DPP4. These results indicate
that the non-proteolytic interaction between DPP4 and integrin
β1 is relevant in diabetic kidney fibrosis.
Mechanistic studies designed to delineate whether effects on
glucose-induced endothelial impairment are related or indepen-
dent of GLP-1/GLP-1R showed that in addition to GLP-1 receptor
effects, DPP4inh with linagliptin exerted direct effects on rat
mesenteric vessels independent of any glucose lowering effect.
The mechanism was shown to be related to its antioxidant effect
through direct radical scavenging (35).
DPP4 inhibitors also exert anti-inflammatory effects. This has
been demonstrated in a non-diabetic animal model of glomerular
injury where alogliptin reduced macrophage infiltration (36) and
likewise in a type 1 diabetic nephropathy model where PKF275-
055 reduced macrophage infiltration and nuclear factor kappa B
activity (37).
It is increasingly evident that although DPP4inh have simi-
lar capacity to improve glucose control they have very different
pharmacokinetic and pharmacodynamic profiles as they bind to
different sites on DPP4 (38). All DPP4 inhibitors can block the
enzymatic (i.e., cleaving) property of DPP4 but may differ in
their ability to influence the co-stimulatory/receptor properties
of DPP4 (2). The mode of clearance of DPP4 inhibitors may also
be relevant (39). DPP4 is highly expressed on the luminal aspect
of the proximal tubular brush border which implies that drugs
which are preferentially filtered by the kidney have better access
to tubular DPP4.
In summary, preclinical studies suggests that DPP4inh offer
renoprotection above and beyond glucose lowering through its
proteolytic, protein–protein interaction, and antioxidant proper-
ties. Given the increased cardiovascular risk in this population,
it would be highly desirable to have a glucose-lowering drug,
which also offers cardiovascular benefit in addition to reno-
protection. Regulatory agencies now mandate that new diabetic
agents undergo cardiovascular assessment prior tomarketing. The
agreed-on primary endpoint for cardiovascular safety analyses is
Major Adverse Cardiovascular Events Plus (MACE-plus), defined
as a composite endpoint consisting of the following adjudicated
events: cardiovascular death, non-fatal myocardial infarction,
non-fatal stroke, and hospitalization for unstable angina (40). The
next section summarizes major clinical trials in this area with
cardiovascular and renal endpoints.
Cardiovascular Aspects
Clinical trials evaluating both cardiovascular and renal end-
points have commenced with the CARMELINA study, which
will include more than 8,000 adults with Type 2 Diabetes and
linagliptin (ClinicalTrials.gov Identifier: NCT01897532). The pri-
mary endpoint will be time to the first occurrence of either
cardiovascular death (including fatal stroke and fatal myocardial
infarction); non-fatal myocardial infarction; non-fatal stroke; or
hospitalization for unstable angina pectoris. The renal outcome
will be measured as a composite of renal death, sustained end-
stage renal disease and sustained decrease of50% eGFR.
AlthoughDPP4inhhave offered somepromisewith pre-clinical
studies and post hoc analyses of clinical trials suggesting a pos-
itive cardiovascular risk profile, a recent randomized placebo
controlled trial (SAVOR-TIMI 53) published in the New Eng-
land Journal of Medicine by Scirica et al. showed no change
in ischemic events but higher hospitalizations for heart failure
with saxagliptin. This study enrolled 16,492 patients with type
2 diabetes with a history of, or were at risk for, cardiovascu-
lar events and followed up for a median of 2.1 years (41). The
EXAMINE study evaluated alogliptin use in patients with type 2
diabetes after acute coronary syndromes showed that there was
no increase in the rates of MACE-plus (42). This randomized
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placebo-controlled trial involved 5,380 patients and had a median
follow up of 18months. The US Food and Drug Administra-
tion (FDA) independent advisory committee recently voted that
the cardiovascular safety profile of these two drugs could be
managed by updating the drugs’ labels (43). Recently, a large
multicentre clinical trial TECOS (Sitagliptin on Cardiovascular
Outcome Study) where 14,671 patients with established cardio-
vascular disease and Type 2 diabetes were randomized to receive
either saxagliptin or placebo (in addition to their usual therapy)
showed no increase in the risk of MACE-plus, hospitalization for
heart failure, or other adverse events (44). Another largemulticen-
tre trial with linagliptin CAROLINA (Cardiovascular Outcome
Study of Linagliptin Versus Glimepiride in Patients with Type 2
Diabetes) is currently in progress (44). As DPP4inh raise GLP-1,
it is also important to take into account the cardiovascular profile
of GLP-1 analogs. In a large retrospective analysis by Best et al.,
patients treated with the GLP1 analog exenatide were shown to
have a 20% reduction in cardiovascular events in comparison
with other glucose-lowering agents (45). However, the studies
that have demonstrated cardiovascular benefit using GLP1 or an
analog do so using supra physiological doses. DPP4inh promote
GLP1 action only within the physiological range andDPP4inh are
likely to have pleiotropic effects independent of their effects on
GLP1 as outlined above. Further details about these trials can be
found in www.clinitrials.gov. There are several DPP4 inhibitors in
clinical use e.g., sitagliptin, saxagliptin, vildagliptin, alogliptin and
linagliptin. They differ structurally and in their pharmacokinetic
profiles and hence the outcome of ongoing trials is important as a
class effect cannot be presumed.
In conclusion, DPP4 inhibitors hold promise as an antifibrotic
and anti-inflammatory agent in kidney diseasewith a large clinical
trial currently underway to evaluate hard renal endpoints. The
jury is still out on whether the risk of heart failure is a class
effect.
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